# 131MIBG to Treat Malignant Pheochromocytoma

> **NCT00028106** · PHASE2 · COMPLETED · sponsor: **Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)** · enrollment: 32 (—)

## Conditions studied

- Pheochromocytoma

## Interventions

- **DRUG:** [131]I-MIBG
- **DRUG:** 6-[18F]Fluorodopamine
- **DRUG:** [123]I-MIBG

## Key facts

- **NCT ID:** NCT00028106
- **Lead sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-12-05
- **Primary completion:** —
- **Final completion:** 2007-01-08
- **Target enrollment:** 32 (—)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00028106

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00028106, "131MIBG to Treat Malignant Pheochromocytoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00028106. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*